Clinical trials: Allogeneic Stem-Cell Transplant
Leukemia, Chronic Myeloid, Myelodysplastic Syndromes
Trial of GVHD Prophylasxis With PTCy or Thymoglobulin in Unrelated SCT
Purpose There is a growing evidence of high efficacy of post-transplantation cyclophocphomide (PTCy)-based GVHD prophylaxis in haploidentical and matched related and unrelated bone marrow transplantation.
- Conditions
- Leukemia, Chronic Myeloid, Myelodysplastic Syndromes, Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
- Trial name
- NCT02627573
- Testing
- Unrelated allogeneic stem cell transplantation, Busulfan, Fludarabine monophosphate
- Where
- Russia
- Volunteers
- 32 people
- Sponsor
- St. Petersburg State Pavlov Medical University
T-Cell Acute Lymphoblastic Leukemia, T-Cell Lymphoblastic Lymphoma
Chidamide Maintenance to Prevent Relapse After Allogeneic Hematopoietic Stem Cell Transplantation in Acute T-Lymphoblastic Leukemia/Lymphoma
This study evaluates whether chidamide maintenance therapy can effectively reduce the risk of relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with high-risk T-cell acute lymphoblastic…
- Trial name
- CHI-HSCT (NCT07774377)
- Testing
- Chidamide, Control Group
- Volunteers
- 132 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Acute Lymphoblastic Leukemia
Allogeneic CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Vaccine After Matched Related Donor Hematopoietic Cell Transplant for the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia
This early phase I trial tests the safety and side effects of allogeneic CMV-specific CD19-CAR T cells plus CMV-MVA vaccine and how well it works in treating patients with high-risk acute lymphoblastic leukemia after a matched…
- Trial name
- NCT06735690
- Testing
- Allogeneic Hematopoietic Stem Cell Transplantation, Anti-CD19-CAR CMV-specific T-lymphocytes, Biospecimen Collection
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- City of Hope Medical Center
Hematologic Malignancy
Study To Evaluate The Safety And Efficacy of PBCLN-010 In Combination With PBCLN-014 in Participants Receiving Allogeneic Hematopoietic Cell Transplantation
This is a Phase 2a, open-label, multicenter study to evaluate the safety and efficacy of HMO (PBCLN-010) and B. infantis (PBCLN-014) on the gut microbiome and GI domination by pathobionts in participants receiving allo-HCT.
- Trial name
- NCT06102213
- Testing
- B. infantis (PBCLN-014) and Human Milk Oligosaccharides (HMO) (PBCLN-010)
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- Prolacta Bioscience
Leukemia, Stem Cell Transplantation
Study of the Trifunctional Antibody FBTA05 and Donor Lymphocyte Infusion in B-cell Lymphoma After Allogeneic Stem Cell Transplantation
This study is an investigator driven, open-label, non-randomized, uncontrolled, dose escalating Phase I/II study evaluating the safety and preliminary efficacy of the trifunctional bispecific antibody FBTA05 in combination with…
- Trial name
- STP-LYM-01 (NCT01138579)
- Testing
- FBTA05
- Where
- Germany
- Sponsor
- Technical University of Munich
Hematologic Malignancies
Phase II Trial of Pentostatin and Targeted Busulfan
The objective of this trial is to determine whether a regimen of pentostatin and busulfan (IV) can facilitate engraftment of human leukocyte antigen (HLA) partially compatible siblings and unrelated donor transplants by using…
- Trial name
- Pento & tBU (NCT00496340)
- Testing
- Pentostatin, Busulfan, Rituximab
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Congenital Hemolytic Anemia, Sickle Cell Disease
Improving the Results of Bone Marrow Transplantation for Patients With Severe Congenital Anemias
People with severe congenital anemias, such as sickle cell anemia and beta-thalassemia, have been cured with bone marrow transplantation (BMT).
- Trial name
- NCT00061568
- Testing
- Peripheral blood hematopoietic progenitor cell (PBPC) transplant, Alemtuzumab, Peripheral blood hematopoietic progenitor cell Apheresis
- Where
- United States
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Hematologic Disorders, Hemoglobinopathies
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
This is a treatment guideline for a second or greater allogeneic hematopoietic stem cell transplant (HSCT) using a reduced intensity conditioning (RIC) in patients with non-malignant or malignant diseases.
- Conditions
- Hematologic Disorders, Hemoglobinopathies, Immunodeficiencies
- Trial name
- NCT01666080
- Testing
- Busulfan, Fludarabine, Total body irradiation
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Chronic Myeloproliferative Disorders, Leukemia
T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies
RATIONALE: Donor peripheral stem cell transplantation may be able to replace bone marrow and immune cells that were destroyed by chemotherapy. Sometimes the transplanted cells from a donor are rejected by the body's normal cells.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00080925
- Testing
- filgrastim, graft-versus-tumor induction therapy, rituximab
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Relapsed Peripheral T-Cell Lymphoma, Refractory Peripheral T-Cell Lymphoma
Pralatrexate Combined With Chidamide Bridging Allogeneic HSCT for Refractory/Relapsed Peripheral T-cell Lymphoma
This is a multicenter, prospective study of Pralatrexate combined with Chidamide bridging Allogeneic Hematopoietic Stem Cell Transplantation for Refractory/Relapsed Peripheral T-cell Lymphoma
- Trial name
- NCT06671717
- Testing
- Pralatrexate combined with Chidamide bridging Allogeneic Hematopoietic Stem Cell Transplantation
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Peking University People's Hospital
Myelodysplastic Syndromes, Leukemia, Myeloid, Acute
A 5 Day Course of Fludarabine and Cytarabine Followed by Full Intensity Allogeneic Stem Cell Transplantation (FA5-Bucy) in Treating Patients With High-risk, Recurrent or Refractory Acute Leukemia and Advanced Myelodysplastic Syndrome
A 5 day course of fludarabine and cytarabine (FA) will be administered followed by full intensity conditioning regimen (Bucy) in the setting of allogeneic stem cell transplantation (SCT).
- Conditions
- Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma
- Trial name
- NCT02328950
- Testing
- Fludarabine and Cytarabine followed by IV busulfan and cyclophosphamide
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Fujian Medical University
Acute Graft Versus Host Disease
Graft-Versus-Host Disease (GVHD) Prophylaxis After Allogeneic Peripheral Blood Hematopoietic Cell Transplantation
The purpose of this research is to compare the effectiveness of Tacrolimus and Rapamycin to Tacrolimus and Methotrexate in the prevention of severe graft-versus-host-disease.
- Trial name
- NCT00803010
- Testing
- Tacrolimus (TAC), Methotrexate (MTX), Rapamycin (RAPA)
- Where
- United States
- Volunteers
- 74 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Cancer Survivor, Chronic Myeloproliferative Disorders
Presence of Donor-Derived DNA in Semen Samples From Cancer Survivors Who Underwent Donor Stem Cell Transplant
RATIONALE: Studying samples of semen from cancer survivors in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Conditions
- Cancer Survivor, Chronic Myeloproliferative Disorders, Leukemia, Lymphoma
- Trial name
- NCT01077440
- Testing
- DNA analysis, polymerase chain reaction, flow cytometry
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Vanderbilt University
Chronic Graft Versus Host Disease
Tissue Immune Landscape of Graft Versus Host Disease After Allogeneic Stem Cell Transplantation (TIL-GVHD)
Graft versus Host Disease (GVHD) is frequent after allogeneic stem cell transplantation (alloSCT). GVHD occurs following 2 patterns : acute GVHD (aGVHD) or chronic GVHD (cGVHD).
- Trial name
- TIL-GVHD (NCT06247150)
- Testing
- Additional blood sample, cGVHD target tissue biopsy
- Where
- France
- Volunteers
- 70 people
- Sponsor
- University Hospital, Bordeaux
Ph+ Acute Lymphoblastic Leukemia (Ph+ALL), Blastic Transformation of Chronic Myeloid Leukemia
Asciminib & Standard-of-Care Integration in Maintenance Therapy for POST Allogeneic Stem Cell Transplant (Allo-HSCT) of Patient With Ph+ B-ALL or Blastic Transformed CML
The goal of this clinical trial is to learn if Asciminib, a first in class allosteric inhibitor, as a add-on maintenance therapy can provides benefits and further prevents relapse in post allogenic hematopoietic stem-cell…
- Conditions
- Ph+ Acute Lymphoblastic Leukemia (Ph+ALL), Blastic Transformation of Chronic Myeloid Leukemia, Philadelphia Chromosome-positive B-cell Acute Lymphoblastic Leukemia (Ph+ B-ALL), Haematopoietic Stem Cell Transplant, Allogeneic
- Trial name
- ASIM-POST Ph+ (NCT07493408)
- Testing
- Asciminib add-on, Imatinib, Dasatinib
- Where
- Hong Kong
- Volunteers
- 45 people
- Sponsor
- The University of Hong Kong
Allogeneic Stem Cell Transplantation
CMV pp65 Specific T Cell Adoptive Immunotherapy in Allogeneic Stem Cell Transplantation for Malignant Disease
The purpose of this study is to determine the safety and feasibility of CMV specific, T cell adoptive immunotherapy in patients who have undergone allogeneic stem cell transplantation for malignant disease.
- Trial name
- CMV-BMT (NCT00611637)
- Testing
- CMV pp65 Specific T Cells
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- H. Kim Lyerly
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
Decitabine Maintenance for Acute Myelogenous Leukemia (AML) and Myelodysplastic Syndrome (MDS) Post Transplant
Primary: To determine the maximum tolerated dose and schedule of decitabine when administered as maintenance therapy after allogeneic hematopoietic stem cell transplantation (alloHSCT) performed for AML or high-risk MDS.
- Trial name
- AML MDS (NCT00986804)
- Testing
- Decitabine
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Washington University School of Medicine
Survivorship, Stem Cell Transplant Complications
AlloLife - Life After Transplantation
Survivors of allo HCT can experience long-term survival, which is however limited by a number of late effects. These will be addressed in AlloLife to improve quality of life (QoL) and survival.
- Trial name
- AlloLife (NCT05087784)
- Testing
- Technology supported, coordinated survivorship care using wearable devices, supportive patient-apps and cardio-oncology physician apps
- Volunteers
- 192 people
- Sponsor
- University Hospital, Essen
Allogeneic Hematopoietic Stem Cell Transplantation, CMV Infection
CMV-TCR-T Cells for Refractory CMV Infection After HSCT
This is a single centre, single arm, open-label, phase I study to evaluate the safety and effectiveness of CMV-TCR-T cell immunotherapy in treating refractory CMV infection after HSCT.
- Trial name
- NCT05089838
- Testing
- CMV-TCR-T cells
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Xiao-Jun Huang
Acute Lymphoblastic Leukemia
CD19 CAR-T Cell Infusion as Consolidation Therapy in Adolescent and Adult Patients With Acute B-ALL Ineligible for Allogeneic HSCT: A Clinical Study
This clinical study investigates a novel treatment option for adolescents and adults with acute B-lymphoblastic leukemia (B-ALL).
- Trial name
- NCT07072494
- Testing
- CD19 CAR-T cells injection
- Where
- 2 sites in China
- Volunteers
- 30 people
- Sponsor
- Zhujiang Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.